Dominique Pape, MD
Urogynecology and Reconstructive Pelvic Surgery · New York, NYNPI 1467730069
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,285 of the $1,503 with a category attached, or 85.5%. It is spread thinly across 9 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $667 and has fallen 51.6% since, to $323 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in NY, where the typical reported total is $2,552.
Across 24 payments — averaging $62.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$334
- Medtronic$275
- Boston Scientific$189
- Coloplast$158
- Axonics, Inc.$144
- Therapeuticsmd, Inc.$122
- plus $282 from 3 others
What the payments were for
- Food & beverage$1,28586%
- Education$21814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 10 | $334 |
| Medtronic(2 entities) | 2 | $275 |
| Boston Scientific | 2 | $189 |
| Coloplast | 1 | $158 |
| Axonics, Inc. | 2 | $144 |
| Therapeuticsmd, Inc. | 1 | $122 |
| AMAG Pharmaceuticals, Inc. | 1 | $119 |
| Astellas Pharma US Inc | 2 | $113 |
| Travere Therapeutics, Inc. | 3 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,503 in reported general payments places this provider in the 30th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.
See all urogynecology and reconstructive pelvic surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 16 | $12,424 |
| PremarinEstrogens, Conjugated | 12 | $5,245 |
| Estradiol | 17 | $2,061 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in New York
- Ido SirotaNew York$12K
- Christina EscobarNew York$12K
- Kimberly FerranteNew York$11K
- Alan GarelyNew York$7K
- Larissa RodriguezNew York$5K
- Melissa LaudanoNew York$4K
- Feven GetanehNew York$4K
- Chandhana PakaNew York$4K
- Svjetlana LozoNew York$2K
- Lisa DabneyNew York$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.